Table 3: Prevalence of HBsAg by year, gender, age group and clinical indications.

HBsAg(+)
n(%)
HBsAg(-)
n(%)
Row total
n(%)
Chi-Square tests
Year 2009 132 (19.97) 529 (80.03) 661 (100) Pearson χ2-test=0.949
p=0.622
2010 75 (18.43) 332 (81.57) 407 (100)
2011 22 (16.67) 110 (80.92) 132 (100)
Gender Male 126 (25.00) 378 (75.00) 504 (100) Pearson χ2-test=19.700
p=0.000
Female 103 (14,80) 593 (85.20) 696 (100)
Age
(years)
0-9 8(11,94) 59(88,06) 67(100) Pearson χ2-test=39.782
p=0.000
10-19 10(11,24) 79(88,76) 89(100)
20-29 99(26,33) 277(73,67) 376(100)
30-39 70(21,67) 253(78,33) 323(100)
40-49 31(18,90) 133(81,10) 164(100)
>50 11(6,08) 170(93,92) 181(100)
Reason of HBsAg screening CARL 38(26,21) 107(73,79) 145(100) Pearson χ2-test =15.281
p=0.0092
Fisher’s Exact Test = 15.330
p=0.008
SS 144(20,25) 567(79,75) 711(100)
BA 18(18,75) 78(81,25) 96(100)
CANRL 12(15) 68(85) 80(100)
PNA 16(10,67) 134(89,33) 150(100)
POA 1(5,56) 17(94,44) 18(100)

CARL: Clinical Abnormalities Related with the Liver; CANRL: Clinical Abnormalities Not Related with the Liver; BA: Biological Abnormalities; SS: Systematic Screening; PNA: Pre-Natal Assessment; POA: Pre-Operative Assessment.